Occupational Asthma Reference

Marabini A, Siracusa A, Stopponi R, Tacconi C, Abbritti G, Outcome of occupational asthma in patients with continuous exposure: a 3-year longitudinal study during pharmacologic treatment, Chest, 2003;124:2372-2376,

Keywords:

Known Authors

Andrea Siracusa, Perugia Andrea Siracusa

If you would like to become a known author and have your picture displayed along with your papers then please get in touch from the contact page. Known authors can choose to receive emails when their papers receive comments.

Abstract

Study objective: To evaluate the effect of treatment with beclomethasone dipropionate (500 µg bid) and salmeterol (50 µg bid) on lung function and respiratory symptoms in 20 subjects with occupational asthma (OA) still exposed to the work environment cause of their disease.

Methods: At enrollment and every 6 months for 3 years, respiratory symptom score (from 0 [no symptoms] to 2 [moderate-to-severe symptoms]), spirometry, methacholine challenge, peak expiratory flow (PEF) variability, and the use of rescue salbutamol were evaluated. During the 3 years of follow-up, 10 subjects were excluded from the study because they retired or changed jobs.

Measurements and results: Symptoms of work-related asthma started 12.6 ± 13.1 years (mean ± SD) before diagnosis. At baseline, mean FEV1 was 80.2% of predicted values and provocative dose of methacholine causing a 20% fall in FEV1 (PD20) was 1,001 ± 1,275 µg; the workers received 2.1 ± 2.4 puffs of salbutamol per day. After 3 years, no significant differences in any of the morbidity outcomes (FEV1, PD20, PEF variability, use of rescue salbutamol, respiratory symptom score) were found as compared with baseline or run-in values.

Conclusions: Regular treatment with inhaled corticosteroids and long-acting bronchodilators seems to prevent respiratory deterioration over a 3-year period in workers with mild-to-moderate persistent OA who were still exposed at work to the environmental cause of their disease.

Plain text: Study objective: To evaluate the effect of treatment with beclomethasone dipropionate (500 ug bid) and salmeterol (50 ug bid) on lung function and respiratory symptoms in 20 subjects with occupational asthma (OA) still exposed to the work environment cause of their disease. Methods: At enrollment and every 6 months for 3 years, respiratory symptom score (from 0 [no symptoms] to 2 [moderate-to-severe symptoms]), spirometry, methacholine challenge, peak expiratory flow (PEF) variability, and the use of rescue salbutamol were evaluated. During the 3 years of follow-up, 10 subjects were excluded from the study because they retired or changed jobs. Measurements and results: Symptoms of work-related asthma started 12.6 +- 13.1 years (mean +- SD) before diagnosis. At baseline, mean FEV1 was 80.2% of predicted values and provocative dose of methacholine causing a 20% fall in FEV1 (PD20) was 1,001 +- 1,275 ug; the workers received 2.1 +- 2.4 puffs of salbutamol per day. After 3 years, no significant differences in any of the morbidity outcomes (FEV1, PD20, PEF variability, use of rescue salbutamol, respiratory symptom score) were found as compared with baseline or run-in values. Conclusions: Regular treatment with inhaled corticosteroids and long-acting bronchodilators seems to prevent respiratory deterioration over a 3-year period in workers with mild-to-moderate persistent OA who were still exposed at work to the environmental cause of their disease.

Full Text

Full text of this reference not available

Please Log In or Register to add the full text to this reference

Associated Questions

There are no associations for this paper.

Please Log In or Register to put forward this reference as evidence to a question.

Bohrf Occupational Asthma Guidelines

This reference has been analysed as part of the BOHRF occupational asthma guidelines. Please click to view the Bohrf occupational asthma guideline data for this reference.

Comments

Please sign in or register to add your thoughts.


Oasys and occupational asthma smoke logo